Imaging techniques for the assessment of ectopic fat in liver and skeletal muscle

Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development

Volumn , Issue , 2015, Pages 99-119

  Hamilton, Gavin ^a   Middleton, Michael S ^a   Heba, Elhamy R ^a   Sirlin, Claude B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Intramyocellular lipid (IMCL); Magnetic resonance imaging (MRI); Magnetic resonance spectroscopy (MRS); Nonalcoholic fatty liver disease (NAFLD); Proton density fat fraction (PDFF)

Indexed keywords

EID: 84948751081     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4471-4920-0_4     Document Type: Chapter

References (87)

1. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106(4):473-81.
2. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53(7):1270-87.
3. Caprio S. Development of type 2 diabetes mellitus in the obese adolescent: a growing challenge. Endocr Pract. 2012;18(5):791-5.
4. Karlas T, Wiegand J, Berg T. Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best Pract Res Clin Endocrinol Metab. 2013;27(2):195-208.
5. Hui E, Xu A, Bo Yang H, Lam KS. Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: role of adipokines. J Diabetes Investig. 2013;4(5):413-25.
6. Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014;59(2):713-23.
7. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in nonalcoholic fatty liver disease. Clin Sci (Lond). 2009;116(7):539-64.
8. Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013;230(2):258-67.
9. Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014. doi: 10.1016/S2213-8587(14)70032-4. Epub ahead of print.
10. Lettner A, Roden M. Ectopic fat and insulin resistance. Curr Diab Rep. 2008;8(3):185-91.
11. Hardy OT, Czech MP, Corvera S. What causes the insulin resistance underlying obesity? Curr Opin Endocrinol Diabetes Obes. 2012;19(2):81-7.
12. Shimabukuro M, Kozuka C, Taira S, Yabiku K, Dagvasumberel M, Ishida M, et al. Ectopic fat deposition and global cardiometabolic risk: new paradigm in cardiovascular medicine. J Med Invest. 2013;60(1-2):1-14.
13. Schwenger KJ, Allard JP. Clinical approaches to nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(7):1712-23.
14. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, ste- atohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917-23.
15. Targher G, Byrne CD. Clinical review: nonalcoholic fatty liver disease: a novel ardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab. 2013;98(2):483-95.
16. Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(7):1724-45.
17. Perseghin G. Muscle lipid metabolism in the metabolic syndrome. Curr Opin Lipidol. 2005;16(4):416-20.
18. Pan DA, Lillioja S, Kriketos AD, Milner MR, Baur LA, Bogardus C, et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes. 1997;46(6):983-8.
19. Petersen KF, Shulman GI. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol. 2002;90(5A):11G-8.
20. Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, Arcelloni C, et al. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes. 1999;48(8):1600-6.
21. Jacob S, Machann J, Rett K, Brechtel K, Volk A, Renn W, et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes. 1999;48(5):1113-9.
22. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes. 2002;51(10):2944-50.
23. Teranishi T, Ohara T, Maeda K, Zenibayashi M, Kouyama K, Hirota Y, et al. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. Metabolism. 2007;56(10):1418-24.
24. Bradford V, Dillon J, Miller M. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease. Hepat Med. 2014;6:1-10.
25. Rabl C, Campos GM. The impact of bariatric surgery on nonalcoholic steatohepatitis. Semin Liver Dis. 2012;32(1):80-91.
26. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011;54(10):2506-14.
27. Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. Exp Diabetes Res. 2012;2012:716-404.
28. Ozturk ZA, Kadayifci A. Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. World J Hepatol. 2014;6(4):199-206.
29. Mahady SE, Webster AC, Walker S, Sanyal A, George J. The role of thiazolidinediones in non-alcoholic ste- atohepatitis - a systematic review and meta analysis. J Hepatol. 2011;55(6):1383-90.
30. Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Calder PC, et al. Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease. Contemp Clin Trials. 2014;37(2):301-11.
31. Eslami L, Merat S, Malekzadeh R, Nasseri- Moghaddam S, Aramin H. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev. 2013;(12):CD008623.
32. Ratziu V. Targeting non-alcoholic fatty liver disease through 11-PHSD1 inhibition. Lancet Diabetes Endocrinol. 2014;2:354-6.
33. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009;51(3):433-45.
34. Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(23):7392-402.
35. Reeder SB, Cruite I, Hamilton G, Sirlin CB. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging. 2011;34(4):729-49.
36. Machann J, Stefan N, Schick F. (1)H MR spectroscopy of skeletal muscle, liver and bone marrow. Eur J Radiol. 2008;67(2):275-84.
37. Dixon WT. Simple proton spectroscopic imaging. Radiology. 1984;153(1):189-94.
38. Glover GH. Multipoint Dixon technique for water and fat proton and susceptibility imaging. J Magn Reson Imaging. 1991;1(5):521-30.
39. Fishbein MH, Gardner KG, Potter CJ, Schmalbrock P, Smith MA. Introduction of fast MR imaging in the assessment of hepatic steatosis. Magn Reson Imaging. 1997;15(3):287-93.
40. Yokoo T, Shiehmorteza M, Hamilton G, Wolfson T, Schroeder ME, Middleton MS, et al. Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. Radiology. 2011;258(3):749-59.
41. Hu HH, Li Y, Nagy TR, Goran MI, Nayak KS. Quantification of absolute fat mass by magnetic resonance imaging: a validation study against chemical analysis. Int J Body Compos Res. 2011;9(3):111-22.
42. Reeder SB, Hu HH, Sirlin CB. Proton density fat- fraction: a standardized MR-based biomarker of tissue fat concentration. J Magn Reson Imaging. 2012;36(5):1011-4.
43. Longo R, Ricci C, Masutti F, Vidimari R, Croce LS, Bercich L, et al. Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography. Invest Radiol. 1993;28(4):297-302.
44. Thomsen C, Becker U, Winkler K, Christoffersen P, Jensen M, Henriksen O. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging. 1994;12(3):487-95.
45. Longo R, Pollesello P, Ricci C, Vidimari R, Croce LS, Bercich L, et al. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging. 1995;5(3):281-5.
46. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288(2):E462-8.
47. Hamilton G, Middleton MS, Bydder M, Yokoo T, Schwimmer JB, Kono Y, et al. Effect of PRESS and STEAM sequences on magnetic resonance spectroscopic liver fat quantification. J Magn Reson Imaging. 2009;30(1):145-52.
48. Pineda N, Sharma P, Xu Q, Hu X, Vos M, Martin DR. Measurement of hepatic lipid: high-speed T2-corrected multiecho acquisition at 1H MR spec- troscopy-a rapid and accurate technique. Radiology. 2009;252(2):568-76.
49. Schick F, Eismann B, Jung WI, Bongers H, Bunse M, Lutz O. Comparison of localized proton NMR signals of skeletal muscle and fat tissue in vivo: two lipid compartments in muscle tissue. Magn Reson Med. 1993;29(2):158-67.
50. Boesch C, Slotboom J, Hoppeler H, Kreis R. In vivo determination of intra-myocellular lipids in human muscle by means of localized 1H-MR-spectroscopy. Magn Reson Med. 1997;37(4):484-93.
51. Kreis R, Boesch C. Spatially localized, one- and two-dimensional NMR spectroscopy and in vivo application to human muscle. J Magn Reson B. 1996;113(2):103-18.
52. Boesch C, Decombaz J, Slotboom J, Kreis R. Observation of intramyocellular lipids by means of 1H magnetic resonance spectroscopy. Proc Nutr Soc. 1999;58(4):841-50.
53. Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis. 2007;11(1):37-54, viii.
54. Graif M, Yanuka M, Baraz M, Blank A, Moshkovitz M, Kessler A, et al. Quantitative estimation of attenuation in ultrasound video images: correlation with histology in diffuse liver disease. Invest Radiol. 2000;35(5):319-24.
55. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745-50.
56. Mottin CC, Moretto M, Padoin AV, Swarowsky AM, Toneto MG, Glock L, et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg. 2004;14(5):635-7.
57. Barry CT, Mills B, Hah Z, Mooney RA, Ryan CK, Rubens DJ, et al. Shear wave dispersion measures liver steatosis. Ultrasound Med Biol. 2012;38(2):175-82.
58. Limanond P, Raman SS, Lassman C, Sayre J, Ghobrial RM, Busuttil RW, et al. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology. 2004;230(1):276-80.
59. Kodama Y, Ng CS, Wu TT, Ayers GD, Curley SA, Abdalla EK, et al. Comparison of CT methods for determining the fat content of the liver. AJR Am J Roentgenol. 2007;188(5):1307-12.
60. Lee SW, Park SH, Kim KW, Choi EK, Shin YM, Kim PN, et al. Unenhanced CT for assessment of macrove- sicular hepatic steatosis in living liver donors: comparison of visual grading with liver attenuation index. Radiology. 2007;244(2):479-85.
61. Birnbaum BA, Hindman N, Lee J, Babb JS. Multidetector row CT attenuation measurements: assessment of intra- and interscanner variability with an anthropomorphic body CT phantom. Radiology. 2007;242(1):109-19.
62. Fazel R, Krumholz HM, Wang Y, Ross JS, Chen J, Ting HH, et al. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med. 2009;361(9):849-57.
63. Hamilton G, Yokoo T, Bydder M, Cruite I, Schroeder ME, Sirlin CB, et al. In vivo characterization of the liver fat (1)H MR spectrum. NMR Biomed. 2011;24(7):784-90.
64. Ren J, Dimitrov I, Sherry AD, Malloy CR. Composition of adipose tissue and marrow fat in humans by 1H NMR at 7 Tesla. J Lipid Res. 2008;49(9):2055-62.
65. Bydder M, Girard O, Hamilton G. Mapping the double bonds in triglycerides. Magn Reson Imaging. 2011;29(8):1041-6.
66. Hu HH, Kan HE. Quantitative proton MR techniques for measuring fat. NMR Biomed. 2013;26(12):1609-29.
67. Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci. 1987;508:333-48.
68. Granot J. Selected volume excitation using stimulated echoes (VEST): applications to spatially localized spectroscopy and imaging. J Magn Reson Imaging. 1986;70:488-92.
69. Frahm J, Merboldt K-D, Hänicke W. Localized proton spectroscopy using stimulated echoes. J Magn Reson Imaging. 1987;72:502-8.
70. Keevil SF. Spatial localization in nuclear magnetic resonance spectroscopy. Phys Med Biol. 2006;51(16):R579-636.
71. Middelton M, Hamilton G, Sirlin CB. Effect of saturation bands on quantitative Liver fat proton MR spectroscopy. In: Proceedings of the RSNA Annual Meeting, Chicago; 2011.
72. De Graff R, Rothman DL. In vivo detection and quantification of scalar coupled 1H NMR resonances. Concepts Magn Reson. 2001;13:32-76.
73. Zandt H, van Der Graaf M, Heerschap A. Common processing of in vivo MR spectra. NMR Biomed. 2001;14:224-32.
74. Vanhamme L, Sundin T, Hecke PV, Huffel SV. MR spectroscopy quantitation: a review of time-domain methods. NMR Biomed. 2001;14(4):233-46.
75. Mierisova S, Ala-Korpela M. MR spectroscopy quantitation: a review of frequency domain methods. NMR Biomed. 2001;14(4):247-59.
76. Szczepaniak LS, Babcock EE, Schick F, Dobbins RL, Garg A, Burns DK, et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol. 1999;276(5 Pt 1):E977-89.
77. Thomas EL, Potter E, Tosi I, Fitzpatrick J, Hamilton G, Amber V, et al. Pioglitazone added to conventional lipid-lowering treatment in familial combined hyper- lipidaemia improves parameters of metabolic control: relation to liver, muscle and regional body fat content. Atherosclerosis. 2007;195(1):e181-90.
78. Reeder SB, Pineda AR, Wen Z, Shimakawa A, Yu H, Brittain JH, et al. Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL): application with fast spin-echo imaging. Magn Reson Med. 2005;54(3):636-44.
79. Kawamitsu H, Kaji Y, Ohara T, Sugimura K. Feasibility of quantitative intrahepatic lipid imaging applied to the magnetic resonance dual gradient echo sequence. Magn Reson Med Sci. 2003;2:47-50.
80. Qayyum A, Goh JS, Kakar S, Yeh BM, Merriman RB, Coakley FV. Accuracy of liver fat quantification at MR imaging: comparison of out-of-phase gradientecho and fat-saturated fast spin-echo techniques-ini- tial experience. Radiology. 2005;237:507-11.
81. Bydder M, Yokoo T, Hamilton G, Middleton MS, Chavez AD, Schwimmer JB, et al. Relaxation effects in the quantification of fat using gradient echo imaging. Magn Reson Imaging. 2008;26(3):347-59.
82. Yokoo T, Bydder M, Hamilton G, Middleton MS, Gamst AC, Wolfson T, et al. Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology. 2009;251(1):67-76.
83. Yu H, Shimakawa A, McKenzie CA, Brodsky E, Brittain JH, Reeder SB. Multiecho water-fat separation and simultaneous R2* estimation with multifrequency fat spectrum modeling. Magn Reson Med. 2008;60(5):1122-34.
84. Yu H, Shimakawa A, Hines CD, McKenzie CA, Hamilton G, Sirlin CB, et al. Combination of complex-based and magnitude-based multiecho water-fat separation for accurate quantification of fat-fraction. Magn Reson Med. 2011;66(1):199-206.
85. Meisamy S, Hines CD, Hamilton G, Sirlin CB, McKenzie CA, Yu H, et al. Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology. 2011;258(3):767-75.
86. Boesch C, Machann J, Vermathen P, Schick F. Role of proton MR for the study of muscle lipid metabolism. NMR Biomed. 2006;19(7):968-88.
87. Szczepaniak L, Dobbins RL, Stein DT, McGarry JD. Bulk magnetic susceptibility effects on the assessment of intra- and extramycellular lipids in vivo. Magn Reson Med. 2001;47:607-10.